Literature DB >> 7580112

Vascular morphology and angiogenesis in glial tumors.

K H Plate1, H D Mennel.   

Abstract

Intracranial tumor classification is paralleled by a grading system that empirically compares tumor entities with "progression stages" of supratentorial gliomas of the adult. This grading system is an integral part of the WHO classification. Glioma progression has originally been defined by descriptive morphology. In this respect, morphological key features of high-grade gliomas (WHO grades III and IV) are microvascular proliferation and the formation of tumor necroses. Glioma progression is now more accurately defined on the molecular genetic level by a stepwise accumulation of oncogene activation and/or tumor suppressor gene inactivation. Angiogenesis occurs during development and progression of glial tumors. Pathological vessels are a hallmark of malignant glioma and it has therefore been suggested that malignant glioma cells are able to induce neovascularization. Despite the exuberant neovascularisation, however, vascular supply may not be sufficient for tumor areas with high cell proliferation, and necroses may develop. Malignant transformation of blood vessel itself is a rare event but may be the underlying mechanism of gliosarcoma development. The recently purified vascular endothelial growth factor (VEGF) is at present the only mitogen known to selectively act on endothelial cells. Growing evidence suggests that VEGF is the key regulator of developmental and pathological angiogenesis. In vivo, VEGF mRNA is upregulated in a subpopulation of malignant glioma cells adjacent to necroses. Since VEGF is hypoxia-inducible, hypoxia may be an important regulator of VEGF mRNA expression and tumor angiogenesis in vivo. Two tyrosine kinase receptors for VEGF are expressed in vessels which invade the tumor, suggesting that tumor angiogenesis is regulated by a paracrine mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7580112     DOI: 10.1016/S0940-2993(11)80292-7

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  33 in total

1.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.

Authors:  Emmanuelle di Tomaso; Matija Snuderl; Walid S Kamoun; Dan G Duda; Pavan K Auluck; Ladan Fazlollahi; Ovidiu C Andronesi; Matthew P Frosch; Patrick Y Wen; Scott R Plotkin; E Tessa Hedley-Whyte; A Gregory Sorensen; Tracy T Batchelor; Rakesh K Jain
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

3.  pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.

Authors:  Jingwen Yao; Caleb Hock Pang Tan; Jacob Schlossman; Ararat Chakhoyan; Catalina Raymond; Whitney B Pope; Noriko Salamon; Albert Lai; Matthew Ji; Phioanh L Nghiemphu; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2019-02-26       Impact factor: 4.130

Review 4.  Update on brain tumor imaging: from anatomy to physiology.

Authors:  S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

Review 5.  Angiogenesis in brain tumors; pathobiological and clinical aspects.

Authors:  P Wesseling; D J Ruiter; P C Burger
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 6.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

7.  Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade.

Authors:  Alan Jackson; Andrea Kassner; Deborah Annesley-Williams; Helen Reid; Xiau-Ping Zhu; Kah-Loh Li
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

8.  Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

Authors:  R D Oehring; M Miletic; M M Valter; T Pietsch; J Neumann; R Fimmers; U Schlegel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

9.  Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

Authors:  Allison F O'Neill; Lei Qin; Patrick Y Wen; John F de Groot; Annick D Van den Abbeele; Jeffrey T Yap
Journal:  J Neurooncol       Date:  2016-08-30       Impact factor: 4.130

10.  Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.

Authors:  David Xu; Donghui Zhou; Khuchtumur Bum-Erdene; Barbara J Bailey; Kamakshi Sishtla; Sheng Liu; Jun Wan; Uma K Aryal; Jonathan A Lee; Clark D Wells; Melissa L Fishel; Timothy W Corson; Karen E Pollok; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2020-05-21       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.